# A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma

> **NCT00628758** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 430 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Symbicort TBH - Turbuhaler
- **DRUG:** beta-II-agonist, inhale steroid

## Key facts

- **NCT ID:** NCT00628758
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 430 (ACTUAL)
- **Last updated:** 2012-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628758, "A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00628758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*